Appendix 4G & Corporate Governance Statement
Melbourne, Australia, 08 October 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read More
CLINUVEL PHARMACEUTICALS LTD 2021 Annual General Meeting - Notice of Meeting & Explanatory Memorandum
Melbourne, Australia, 08 October 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read More
Notification regarding unquoted securities - CUV
Melbourne, Australia, 16 September 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read More
CLINUVEL Investor Webinar Financial Results Year Ended 30 June 2021
Melbourne, Australia, 27 August 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read More
CLINUVEL Communiqué IV
Dear Shareholders, Friends Introduction With satisfaction, we look back at an eventful...
Read More
Corporate Presentation - FY2021 Results
Melbourne, Australia, 26 August 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read More
Appendix 4E and Preliminary Financial Report
Melbourne, Australia, 26 August 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read More
CLINUVEL Delivers Record Revenues and Profit
Melbourne, Australia, 26 August 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read More
Dividend/Distribution - CUV
Melbourne, Australia, 26 August 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read More
SCENESSE® To Be Evaluated in Xeroderma Pigmentosum Variant (XPV)
CLINUVEL today announced that it has reached agreement with clinical and academic...
Read More
SCENESSE® Granted Market Access In Israel
CLINUVEL today announced that SCENESSE® (afamelanotide 16mg) has been added to the...
Read More
Media Release – CLINUVEL to Trial Innovative Drug in Stroke
The drug afamelanotide will be used for the first time in patients...
Read More
Media Release – TGA approves Australian drug to protect patients from light and sun
New Australian-developed drug approved by TGA for metabolic disorder erythropoietic protoporphyria (EPP)...
Read More
Australian TGA approves SCENESSE®
Executive summary SCENESSE® approved by Australian TGA under Priority Review First approved...
Read More
Media Release - First patient dosed in SCENESSE® DNA Repair Program
Xeroderma pigmentosum (XP) patient receives SCENESSE® treatment In the search for a...
Read More